(Q43935114)

English

Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial

scientific article published in March 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

phase II clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

D J T Wagener

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

J A Wils

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

T C Kok

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

A Planting

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

M L Couvreur

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

B Baron

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

publication date

1 March 2002

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

38

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

648-653

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Multimodality treatment of locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

No standard treatment is available for advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial with ifosfamide in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of cisplatin in adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmentation of chemically induced pancreatic and bronchial cancers by epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Autocrine growth factors and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900319-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(01)00319-7

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43935114&oldid=2104497643"